| 1 | CDKN2B, STAU1, TINCR
|
| E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis.
|
| Xu TP, Wang YF, Xiong WL, Ma P, Wang WY, Chen WM, Huang MD, Xia R, Wang R, Zhang EB, Liu YW, De W, Shu YQ.
|
| Cell Death Dis 8(6):e2837. doi: 10.1038/cddis.2017.205.
2017
|
| 2 | CDKN2B
|
| CDKN2B Regulates TGFβ Signaling and Smooth Muscle Cell Investment of Hypoxic Neovessels.
|
| Nanda V, Downing KP, Ye J, Xiao S, Kojima Y, Spin JM, DiRenzo D, Nead KT, Connolly AJ, Dandona S, Perisic L, Hedin U, Maegdefessel L, Dalman J, Guo L, Zhao X, Kolodgie FD, Virmani R, Davis HR Jr, Leeper NJ.
|
| Circ Res 118(2):230-40. doi: 10.1161/CIRCRESAHA.115.307906. Epub 2015 Nov 23.
2016
|
| 3 | CDKN2B
|
| Hypermethylation of p15 gene associated with an inferior poor long-term outcome in childhood acute lymphoblastic leukemia.
|
| Mai H, Liu X, Chen Y, Li C, Cao L, Chen X, Chen S, Liu G, Wen F.
|
| J Cancer Res Clin Oncol 142(2):497-504.
2016
|
| 4 | CDKN2A, CDKN2B
|
| Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.
|
| Gonçalves AC, Cortesão E, Oliveiros B, Alves V, Espadana AI, Rito L, Magalhães E, Pereira S, Pereira A, Costa JM, Mota-Vieira L, Sarmento-Ribeiro AB.
|
| Clin Exp Med 16(3):333-43. doi: 10.1007/s10238-015-0357-2. Epub 2015 May 17.
2016
|
| 5 | ASXL1, CDKN2B
|
| Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
|
| Wu X, Bekker-Jensen IH, Christensen J, Rasmussen KD, Sidoli S, Qi Y, Kong Y, Wang X, Cui Y, Xiao Z, Xu G, Williams K, Rappsilber J, Sønderby CK, Winther O, Jensen ON, Helin K.
|
| Cell Res 25(11):1205-18. doi: 10.1038/cr.2015.121.
2015
|
| 6 | CDKN2A, CDKN2B, STAT5B
|
| Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.
|
| Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.
|
| Immunology 145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15.
2015
|
| 7 | CDKN2B
|
| Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma.
|
| Jafri M, Wake NC, Ascher DB, Pires DE, Gentle D, Morris MR, Rattenberry E, Simpson MA, Trembath RC, Weber A, Woodward ER, Donaldson A, Blundell TL, Latif F, Maher ER.
|
| Cancer Discov 5(7):723-9. doi: 10.1158/2159-8290.CD-14-1096. Epub 2015 Apr 14.
2015
|
| 8 | CDKN1B, CDKN2B, RB1, SMAD2
|
| Smad2 overexpression reduces the proliferation of the junctional epithelium.
|
| Alotaibi MK, Kitase Y, Shuler CF.
|
| J Dent Res 93(9):898-903. doi: 10.1177/0022034514543016. Epub 2014 Jul 14.
2014
|
| 9 | CDKN2A, CDKN2B
|
| Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
|
| Wang X, Zhu YB, Cui HP, Yu TT.
|
| Tumour Biol 35(9):9035-43. doi: 10.1007/s13277-014-2054-2. Epub 2014 Jun 8.
2014
|
| 10 | CDKN2B
|
| Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.
|
| Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, Maegdefessel L, Quertermous T, Leeper NJ.
|
| J Clin Invest 124(3):1083-97. doi: 10.1172/JCI70391. Epub 2014 Feb 17.
2014
|
| 11 | CDKN2B, ZBTB17
|
| Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1
|
| Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML, Rabourdin-Combe C, Lotteau V, Kempkes B, Tommasino M, Gruffat H, Manet E.
|
| Nucleic Acids Res. Sep;42(15):9700-16. doi: 10.1093/nar/gku697. Epub 2014 Aug 4. 2014
|
| 12 | CDKN1B, CDKN2B, KDM2A
|
| Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.
|
| Gao R, Dong R, Du J, Ma P, Wang S, Fan Z.
|
| Mol Cell Biochem 379(1-2):115-22. doi: 10.1007/s11010-013-1633-7. Epub 2013 Apr 5.
2013
|
| 13 | CDKAL1, CDKN2A, CDKN2B
|
| The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
|
| Peng F, Hu D, Gu C, Li X, Li Y, Jia N, Chu S, Lin J, Niu W.
|
| Gene 531(2):435-43. doi: 10.1016/j.gene.2013.08.075. Epub 2013 Sep 4.
2013
|
| 14 | CDKN2B
|
| Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation.
|
| Leeper NJ, Raiesdana A, Kojima Y, Kundu RK, Cheng H, Maegdefessel L, Toh R, Ahn GO, Ali ZA, Anderson DR, Miller CL, Roberts SC, Spin JM, de Almeida PE, Wu JC, Xu B, Cheng K, Quertermous M, Kundu S, Kortekaas KE, Berzin E, Downing KP, Dalman RL, Tsao PS, Schadt EE, Owens GK, Quertermous T.
|
| Arterioscler Thromb Vasc Biol 33(1):e1-e10. doi: 10.1161/ATVBAHA.112.300399. Epub 2012 Nov 15.
2013
|
| 15 | CDKN2A, CDKN2B, DLC1
|
| Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
|
| Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
|
| Cancer Res 72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25.
2012
|
| 16 | CDKN2B, MBD4, TDG, ZNF217
|
| TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex.
|
| Thillainadesan G, Chitilian JM, Isovic M, Ablack JN, Mymryk JS, Tini M, Torchia J.
|
| Mol Cell 46(5):636-49. doi: 10.1016/j.molcel.2012.03.027. Epub 2012 May 3.
2012
|
| 17 | CDKN2B, CDKNA
|
| Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
|
| Guney S, Bertrand P, Jardin F, Ruminy P, Kerckaert JP, Tilly H, Bastard C.
|
| Genes Chromosomes Cancer 50(9):715-25. doi: 10.1002/gcc.20893. Epub 2011 Jun 2.
2011
|
| 18 | CDKN2A, CDKN2B, CDKN2B-AS1
|
| Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.
|
| Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B.
|
| PLoS Genet 6(4):e1000899. 2010
|
| 19 | CDKN2B, GFI1, ZBTB17
|
| Gfi-1 represses CDKN2B encoding p15INK4B through interaction with Miz-1.
|
| Basu S, Liu Q, Qiu Y, Dong F.
|
| Proc Natl Acad Sci U S A 106(5):1433-8. Epub 2009 Jan 22. 2009
|
| 20 | CDKN2B, RTEL1, TNFRSF6B
|
| Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
|
| Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, McCoy L, O'Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson AL, Smirnov I, Tihan T, Wiemels J, Yang P, Wiencke JK.
|
| Nat Genet 41(8):905-8. Epub 2009 Jul 5.PMID: 19578366 2009
|
| 21 | CDKN2A, CDKN2B
|
| Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
|
| Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, Kim TY, Min HJ, She CJ, Kang HJ, Shin HY, Ahn HS, Yoon SS, Kim BK, Shin HR, Han KS, Cho HI, Lee DS.
|
| Cancer Genet Cytogenet 195(1):59-65.PMID: 19837270 2009
|
| 22 | CDKN2B
|
| p15 promoter methylation - a novel prognostic marker in glioblastoma patients.
|
| Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel WI, Rahnenführer J, Urbschat S.
|
| Int J Oncol 34(6):1743-8.PMID: 19424593 2009
|
| 23 | CDKN2A, CDKN2B
|
| Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.
|
| Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, Locatelli F, Giorda R, Zuffardi O.
|
| Hum Genet 126(4):511-20. Epub 2009 May 30.PMID: 19484265 2009
|
| 24 | CDKN2B
|
| Clinical risk factors, DNA variants, and the development of type 2 diabetes.
|
| Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L.
|
| N Engl J Med 359(21):2220-32.PMID: 19020324 2008
|
| 25 | CDKN2B, IGFBP2, CDKAL1, NIDDM18
|
| Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.
|
| Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S.
|
| Science 316(5829):1331-6. Epub 2007 Apr 26. 2007
|
| 26 | CDKN2A,CDKN2B
|
| A common allele on chromosome 9 associated with coronary heart disease.
|
| McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC.
|
| Science 316(5830):1488-91. Epub 2007 May 3. 2007
|
| 27 | CDKN2A,CDKN2B, ANRIL
|
| A common variant on chromosome 9p21 affects the risk of myocardial infarction.
|
| Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K.
|
| Science 316(5830):1491-3. Epub 2007 May 3. 2007
|
| 28 | CDKN2A, CDKN2B, MNST
|
| Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
|
| Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.
|
| J Med Genet 43(1):39-47. Epub 2005 Jun 3. 2006
|
| 29 | CDKN2A, CDKN2B
|
| The regulation of INK4/ARF in cancer and aging.
|
| Kim WY, Sharpless NE.
|
| Cell 127(2):265-75. Review. 2006
|
| 30 | CDKN2A, CDKN2B
|
| Loss of 9p21 is embedded in a complex but consistent pattern of genomic imbalances in oral squamous cell carcinomas.
|
| Gebhart E, Liehr T, Wolff E, Wiltfang J, Koscielny S, Ries J.
|
| Cytogenet Genome Res 101(2):106-12. 2003
|
| 31 | CDKN2A, CDKN2B
|
| Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
|
| Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ.
|
| Genes Chromosomes Cancer 35(2):176-81. 2002
|
| 32 | CDKN2A, CDKN2B, MNST
|
| A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
|
| Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J , Bishop DT.
|
| Hum Mol Genet 10(1):55-62. 2001
|
| 33 | CDKN2A, CDKN2B
|
| Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
|
| Bisogna M, Calvano JE, Ho GH, Orlow I, Cordon-Cardo C, Borgen PI, Van Zee KJ.
|
| Cancer Genet Cytogenet 125(2):131-8. 2001
|
| 34 | CDKN2A, CDKN2B
|
| Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
|
| Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y.
|
| Cancer Genet Cytogenet 120(2):91-8. 2000
|
| 35 | CDKN2A, CDKN2B
|
| Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.
|
| Orlow I, et al.
|
| J Natl Cancer Inst 91(1):73-9. 1999
|
| 36 | CDKN2A, CDKN2B, IFN1@, TSG9A
|
| Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis.
|
| Watson JEV, et al.
|
| Genome Res 9(3):226-33. 1999
|
| 37 | CDKN2B
|
| Prognostic role of p27Kip1 and apoptosis in human breast cancer.
|
| Wu J, et al.
|
| Br J Cancer 79(9-10):1572-8. 1999
|
| 38 | CDKN2A, CDKN2B
|
| Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia.
|
| Maloney KW, et al.
|
| Blood 93(7):2380-5. 1999
|
| 39 | CDKN2A, CDKN2B
|
| Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
|
| Simon M, Koster G, Menon AG, Schramm J.
|
| Acta Neuropathol (Berl) 98(5):444-52 1999
|
| 40 | CDKN2A, CDKN2B
|
| Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
|
| Walker GJ, et al.
|
| Genes Chromosomes Cancer 22 : 157-163. 1998
|
| 41 | CDKN2A, CDKN2B, CMM2, TSG9A
|
| Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
|
| Matsumura Y, et al.
|
| Arch Dermatol Res 290 : 175-180. 1998
|
| 42 | CDKN2A, CDKN2B, CDKN2C, CDKN2D
|
| Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
|
| Drexler HG.
|
| Leukemia 12 : 845-859. 1998
|
| 43 | CDKN2B, CMM2
|
| Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
|
| Elenitoba-Johnson KS, et al.
|
| Blood 91 : 4677-4685. 1998
|
| 44 | CDKN2A, CDKN2B, HLF, TCF3
|
| Different patterns of homozygous p16INK4A and P15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations.
|
| Maloney KW, et al.
|
| Leukemia 12 : 1417-1421. 1998
|
| 45 | CDKN2B
|
| High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene.
|
| Uchida T, et al.
|
| Leuk Lymphoma 32(1-2):9-18. 1998
|
| 46 | CDKN2A, CDKN2B, MNST
|
| Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
|
| Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M.
|
| Cancer Res 58(11):2298-303. 1998
|
| 47 | CDKN2A, CDKN2B, CMM2
|
| Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
|
| Liu L, et al.
|
| Genes Chromosomes Cancer 19 : 52-54. 1997
|
| 48 | CDKN2A, CDKN2B, TSG9A
|
| Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
|
| Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
|
| Cancer Res 57(13):2703-9. 1997
|
| 49 | CDKN2B
|
| Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor.
|
| Tsubari M, Tiihonen E, Laiho M.
|
| Cancer Res 57(14):2966-73. 1997
|
| 50 | CDKN2A, CDKN2B, TSG9A
|
| Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias.
|
| Cayuela JM, Gardie B, Sigaux F.
|
| Blood 90(9):3720-6. 1997
|
| 51 | CDKN2A, CDKN2B, CDKN2C, TSG9A
|
| Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma.
|
| Iolascon A, et al.
|
| Genes Chromosomes Cancer 15 : 217-222. 1996
|
| 52 | D9S974, D9S975, D9S976, D9S977, D9S978, CDKN2A, CDKN2B, TSG9A
|
| Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
|
| Ohta M, et al.
|
| Int J Cancer 65 : 762-767. 1996
|
| 53 | CDKN2A, CDKN2B, CMM2, TSG9A
|
| Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
|
| Jagasia AA, et al.
|
| Cancer Lett 105 : 91-103. 1996
|
| 54 | CDKN2A, CDKN2B, TSG9A
|
| Deletion of CDK4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. (abstr)
|
| Koduru PRK, et al.
|
| Blood 86(8):2900-5. 1995
|
| 55 | TSG9A, CDKN2A, CDKN2B
|
| Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
|
| Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, et al.
|
| Hum Mol Genet 4(10):1883-7. 1995
|
| 56 | CDKN2D, CDKN2A, CDKN2B
|
| Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d an inhibitor of cyclin D-dependent kinases.
|
| Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR.
|
| Genomics 29(3):623-30. 1995
|
| 57 | TSG9A, CDKN2B
|
| Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
|
| Glendening JM, et al.
|
| Cancer Res 55 : 5531-5535. 1995
|
| 58 | CDKN2A, CDKN2B, TSG9A
|
| Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
|
| Shimizu T, et al.
|
| Int J Cancer 63 : 616-620. 1995
|
| 59 | TSG9A, CDKN2A, CDKN2B
|
| Codeletion of p15 and p16 in primary malignant mesothelioma.
|
| Xiao S, et al.
|
| Oncogene 11 : 511-515. 1995
|
| 60 | CDKN2A, CDKN2B
|
| Candidate tumor-suppressor genes MTS1 (p16ink4A) and MTS2 (p15ink4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias.
|
| Hebert J, et al.
|
| Blood 84 : 4038-4044. 1994
|
| 61 | TSG9A, CDKN2A, CDKN2B
|
| Deletion of p16 and p15 genes in brain tumors.
|
| Jen J, et al.
|
| Cancer Res 54 : 6353-6358. 1994
|
| 62 | CDKN2B, CDKN2C
|
| Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
|
| Guan KL, et al.
|
| Genes Dev 8 : 2939-2952. 1994
|